#United States #New York #Gross Law Firm #Cerevel Therapeutics #ABBV

Notice to Cerevel Therapeutics Shareholders

Attention shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV): The Gross Law Firm seeks to inform you about a crucial lead plaintiff deadline approaching on June 3, 2025. This ongoing legal case may impact your investment, especially if you acquired shares during the class action period.

Class Period Details

This lawsuit encompasses all individuals or entities who:

• - Sold or disposed of Cerevel's publicly-traded common stock from October 11, 2023, to August 1, 2024.
• - Held shares as of January 8, 2024, and had voting rights in the merger involving Cerevel and AbbVie Inc.
• - Sold shares around the time Bain Capital purchased additional Cerevel shares on October 16, 2023.

Allegations in the Lawsuit

The allegations highlight that Cerevel's stock price was manipulated due to misleading statements made during the October secondary stock offering. The offering documents allegedly omitted critical information regarding AbbVie's interest in acquiring Cerevel for a price significantly higher than the $22.81 per share offering price, causing investor losses.

Moreover, Bain Capital, which is Cerevel’s controlling shareholder, allegedly benefited from this misleading information by acquiring shares at an artificially low price. When AbbVie announced its acquisition of Cerevel at $45 per share on December 6, 2023, Bain reaped substantial profits based on these manipulations. The proxy statement released by Cerevel on January 18, 2024 further misrepresented details surrounding AbbVie’s interest.

Action Steps for Investors

Shareholders who wish to participate in this class action should promptly register their information online at this link. Enrolling does not require you to be a lead plaintiff, and by registering, you gain access to portfolio monitoring tools that provide ongoing updates throughout the case.

The registration deadline for becoming a lead plaintiff is June 3, 2025. Companies or individuals who have suffered losses due to misleading statements are encouraged to act swiftly.

About The Gross Law Firm

The Gross Law Firm is a nationally recognized group dedicated to protecting investors' rights. The firm works to ensure accountability from companies regarding their statements and practices. They understand that transparency is vital for making informed investment decisions. If you believe you have been a victim of misleading practices by Cerevel Therapeutics, reaching out to the Gross Law Firm could be an important step toward recovery.

For more inquiries, you may contact the Gross Law Firm, located at 15 West 38th Street, 12th Floor, New York, NY, 10018. You can also reach them via email at [email protected] or by phone at (646) 453-8903.

The time for action is now, and shareholders are urged not to delay registration as the deadline approaches.

Conclusion

In closing, the unfolding events surrounding Cerevel Therapeutics Holdings, Inc. present both challenges and opportunities for its shareholders. Staying informed and taking timely measures could significantly impact your investment recovery in the face of this ongoing litigation.